Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 40OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

Everolimus 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Malignancies × Clear all
NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown
35 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡